## We Claim:

1. The use of a 5HT<sub>1</sub> agonist in the manufacture of a medicament for administration to a human exhibiting prodrome symptoms of migraine in order to prevent the headache phase of migraine.

5

- 2. The use according to claim 1 wherein the 5HT<sub>1</sub> agonist is selected from the group consisting of sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, frovatriptan and almotriptan.
- 10 3. The use according to claim 2 wherein the  $5HT_1$  agonist is sumatriptan.
  - 4. The use according to claim 3 wherein 2 mg to 100 mg of sumatriptan are administered.

15

- 5. The use according to claim 2 wherein the  $5HI_1$  agonist is naratriptan.
- 6. The use according to claim 5 wherein 0.25 mg to 2.5 mg of 20 naratriptan are administered.
  - 7. The use according to claim 2 wherein the  $5HT_1$  agonist is rizatriptan.
- 25 8. The use according to claim 7 wherein 5 mg to 10 mg of rizatriptan are administered.
  - 9. The use according to claim 2 wherein the 5HT<sub>1</sub> agonist is zolmitriptan.

## 22/27

- 10. The use according to claim 9 wherein 1 mg to 5 mg of zolmitriptan are administered.
  - 11. The use according to claim 2 wherein the 5HT<sub>1</sub> agonist is eletriptan.

5

- 12. The use according to claim 11 wherein 20 mg to 80 mg of eletriptan are administered.
- 13. The use according to claim 2 wherein the  $5HT_1$  agonist is 10 frovatriptan.
  - 14. The use according to claim 13 wherein 2.5 mg to 40 mg of frovatriptan are administered.
- 15 The use according to claim 2 wherein the  $5HT_1$  agonist is almotriptan.
  - 16. The use according to claim 15 wherein 12.5 mg to 25 mg of almotriptan are administered.

- 17. A method of preventing the headache phase of migraine in a human comprising administration of a migraine headache phase-preventing amount of a 5HT<sub>1</sub> agonist to a human exhibiting prodrome symptoms of migraine.
- 25 18. A pharmaceutical composition comprising a 5HT<sub>1</sub> agonist as active ingredient for administration during the prodrome phase of migraine in order to prevent the headache phase of a migraine.



## 23/27

- 19. A preemptive prophylaxis migraine method including the steps of: determining prodromal symptoms of migraine; and administering an anti-migraine medication.
- 5 20. A preemptive prophylaxis migraine method as set forth in claim 19, wherein the step of determining prodromal symptoms of migraine includes performing cognitive tests to determine prodromal symptoms of migraine.
- 21. A preemptive prophylaxis migraine method as set forth in claim 20, wherein the step of performing cognitive tests includes performing a simple reaction time test, a running memory continuous performance test, a matching to sample test, and a mathematical processing test.
- A preemptive prophylaxis migraine method as set forth in claim 21,
   wherein the step of performing cognitive tests is preceded by the steps of performing a Stanford sleepiness scale test and a mood scale test.
  - 23. A preemptive prophylaxis migraine method as set forth in claim 20, including the step of administering and scoring the cognitive tests by a computer, and storing the scores received on the cognitive tests in the computer.
    - 24. A preemptive prophylaxis migraine method as set forth in claim 23, including converting the stored scores from the cognitive tests into a stanine score.

25

20

25. A preemptive prophylaxis migraine method as set forth in claim 24, including comparing the stanine score to a baseline score, and indicating when there is a difference between the baseline and the stanine score as indicative of the onset of the prodromal symptoms of migraine.



## 24/27

- 26. A preemptive prophylaxis migraine method as set forth in claim 20, wherein the step of administering an anti-migraine medication includes administering a 5HT<sub>1</sub> agonist as the anti-migraine medication.
- 5 27. A preemptive prophylaxis migraine method as set forth in claim 26, wherein the 5HT<sub>1</sub> agonist is selected from the group consisting of sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, frovatriptan and almotriptan.
- 28. A preemptive prophylaxis migraine method as set forth in claim 20, wherein the step of administering an anti-migraine medication includes administering a non-narcotic analgesic.
  - 29. A preemptive prophylaxis migraine method as set forth in claim 28, wherein the non-narcotic analgesic is selected from the group consisting of acetylsalicylic acid (aspirin); nonsteroidal anti-inflammatory drugs (NSAIDs); and a combination of 4'-hydroxyacetanilide (acetaminophen), acetylsalicylic acid, and caffeine.
- 30. A preemptive prophylaxis migraine method as set forth in claim 29, wherein the nonsteroidal anti-inflammatory drugs include COX-2 inhibitors.
  - 31. A preemptive prophylaxis migraine method as set forth in claim 19, wherein the step of administering an anti-migraine medication includes administering a 5HT<sub>1</sub> agonist as the anti-migraine medication.

32. A preemptive prophylaxis migraine method as set forth in claim 31, wherein the 5HT<sub>1</sub> agonist is selected from the group consisting of sumatriptan, naratriptan, rizatriptan, zolmitriptan, eletriptan, frovatriptan and almotriptan.

25

- 33. A preemptive prophylaxis migraine method as set forth in claim 19, wherein the step of administering an anti-migraine medication includes administering a non-narcotic analgesic as the anti-migraine medication.
- 5 34. A preemptive prophylaxis migraine method as set forth in claim 33. wherein the non-narcotic analgesic is selected from the group consisting of acetylsalicylic acid (aspirin); nonsteroidal anti-inflammatory drugs; and a combination of 4'-hydroxyacetanilide (acetaminophen), acetylsalicylic acid, and caffeine.

10

- 35. A preemptive prophylaxis migraine method as set forth in claim 34. wherein the nonsteroidal anti-inflammatory drugs include COX-2 inhibitors.
- A method of preventing the headache phase of migraine in a human 36. comprising administering a migraine headache phase-preventing amount of a nonnarcotic analgesic to a human exhibiting prodrome symptoms of migraine.

- 37. A method of preventing the headache phase of migraine in a human as set forth in claim 36, wherein the non-narcotic analgesic is selected from the group consisting of acetylsalicylic acid (aspirity); nonsteroidal anti-inflammatory drugs; and a combination of 4'-hydroxyacetanilide (acetaminophen), acetylsalicylic acid, and caffeine.
- 38. A preemptive prophylaxis migraine method as set forth in claim 37, wherein the nonsteroidal anti-inflammatory drugs include acetominophen, 25 ibuprofen, naproxen, and indomethacin.
  - 39. A preemptive prophylaxis migraine method as set forth in claim 37, wherein the nonsteroidal anti-inflammatory drugs include COX-2 inhibitors.



40. A preemptive prophylaxis migraine method as set forth in claim 39, wherein the COX-2 inhibitors include celecoxib and rofecoxib.

add 7
A3